NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Pr
Post# of 174
(Total Views: 73)
Posted On: 09/04/2025 3:50:13 PM
NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data demonstrating that CNM-Au8(R) improved mitochondrial function, reduced inflammation, and restored cellular metabolism in a novel dopaminergic neuron model of Parkinson’s disease (PD). The findings, presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting in New York City, showed CNM-Au8 corrected metabolic imbalances, normalized dysregulated gene expression, and exhibited a favorable safety profile with no toxicity observed in PD neurons. Conducted in collaboration with the Salk Institute and supported by MJFF funding, the study underscores CNM-Au8’s potential as a neuroprotective therapy for both familial and sporadic PD.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data demonstrating that CNM-Au8(R) improved mitochondrial function, reduced inflammation, and restored cellular metabolism in a novel dopaminergic neuron model of Parkinson’s disease (PD). The findings, presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting in New York City, showed CNM-Au8 corrected metabolic imbalances, normalized dysregulated gene expression, and exhibited a favorable safety profile with no toxicity observed in PD neurons. Conducted in collaboration with the Salk Institute and supported by MJFF funding, the study underscores CNM-Au8’s potential as a neuroprotective therapy for both familial and sporadic PD.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)